RSPO3参与新生内膜形成及调节血管平滑肌细胞功能的实验研究  

RSPO3 in the process of neointima formation and the function of vascular smooth muscle cells

作　　者：渠航 陈冲[1] 罗雪阳 丁晓维 QU Hang;CHEN Chong;LUO Xue-yang;DING Xiao-wei(Institute for Cardiovascular Development and Regenerative Medicine,Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine,Shanghai 200082,China)

机构地区：[1]上海交通大学医学院附属新华医院心血管发育与再生医学研究所,上海市200082

出　　处：《中国心血管病研究》2022年第7期637-642,共6页Chinese Journal of Cardiovascular Research

基　　金：国家自然科学基金(82101441);上海市卫生健康委员会科研项目(20214Y0118)。

摘　　要：目的探究RSPO3是否参与小鼠血管损伤后新生内膜形成以及对平滑肌细胞功能的调控作用。方法本实验于2021年5月至2022年2月在新华医院发育与再生医学研究所完成。构建小鼠股动脉导丝损伤模型,检测股动脉RSPO3的表达;在血小板衍生生长因子-BB(PDGF-BB)诱导人主动脉平滑肌细胞(HASMCs)增殖及迁移的细胞模型中检测RSPO3的表达,观察小干扰RNA敲低RSPO3后PDGF-BB对HASMCs作用的变化。结果小鼠股动脉损伤后RSPO3表达升高,且主要集中表达在新生内膜区域;PDGF-BB处理HASMCs后RSPO3时间依赖性表达升高,敲低RSPO3抑制PDGF-BB诱导的HASMCs增殖和迁移。结论RSPO3参与小鼠新生内膜形成的过程,促进PDGF-BB诱导的HASMCs增殖及迁移。Objective To investigate the effect of RSPO3 on neointima formation and function of vascular smooth muscle cells with pathological conditions.Methods This study was performed at the laboratory in Xinhua Hospital from May 2021 to February 2022.The mouse femoral artery injury model was established and the expression of RSPO3 in the injured femoral artery was detected.The expression of RSPO3 was detected on human aortic smooth muscle cells(HASMCs)after treatment with PDGF-BB;RSPO3 was knocked down by small interfering RNA to observe whether the effect of PDGF-BB on HASMCs changes.Results The expression of RSPO3 in the femoral artery of mice was observably increased and mainly existed in the neointima region after femoral artery injury.The expression of RSPO3 protein increased in a time dependent manner after the treatment with PDGF-BB on HASMCs and knockdown of RSPO3 counteracted PDGF-BB-induced proliferation and migration of HASMCs.Conclusion RSPO3 involvs in the process of mouse neointima formation.RSPO3 promotes PDGF-BB induced proliferation and migration of HASMCs.

关 键 词：RSPO3 新生内膜形成 PDGF-BB 血管平滑肌细胞 

分 类 号：Q95-33[生物学—动物学] R54[医药卫生—心血管疾病]